Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the airways. There is evidence that maintenance treatment with inhaled corticosteroids (ICS) in COPD results in a reduction in the mean rate of exacerbations, and improvement in quality of life and lung function [1]. However, ICS therapy has been associated with increased risk of oropharyngeal candidiasis, hoarseness and pneumonia [1]. In COPD, ICS are now recommended in cases of frequent exacerbations and severe obstruction [2]. Blood eosinophil counts, but not FeNO, may predict airway eosinophilic inflammation http://ow.ly/WXgkA

[1]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[2]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[3]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[4]  M. Henket,et al.  Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation , 2013, BMC Pulmonary Medicine.

[5]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[6]  R. Louis,et al.  Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. , 2011, Cytokine.

[7]  R. Louis,et al.  Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma , 2010, Thorax.

[8]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[9]  T. Lasserson,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[10]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[11]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[12]  R. Djukanović,et al.  Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[13]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.